NCT04795843

Brief Summary

This effectiveness trial will investigate if patients with hip dysplasia randomised to exercise and patient education have a different mean change in self-reported pain measured by the Copenhagen Hip and Groin Outcome Score (HAGOS) compared with those randomised to usual care over a six-month follow-up period. Participating patients will be allocated to either exercise and patient education or usual care. Alongside this, a health-economic study and a process-evaluation study will be conducted.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for not_applicable

Timeline
19mo left

Started Apr 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress76%
Apr 2021Dec 2027

First Submitted

Initial submission to the registry

March 9, 2021

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 12, 2021

Completed
1 month until next milestone

Study Start

First participant enrolled

April 16, 2021

Completed
6.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2027

Expected
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2027

Last Updated

December 5, 2025

Status Verified

November 1, 2025

Enrollment Period

6.2 years

First QC Date

March 9, 2021

Last Update Submit

December 4, 2025

Conditions

Keywords

Hip Dislocation, CongenitalExercisePatient educationUsual careEffectivenessCost-effectivenessProcess evaluationPeriacetabular osteotomy

Outcome Measures

Primary Outcomes (1)

  • Change in self-reported pain measured with The Copenhagen Hip and Groin Outcome Score (HAGOS) (continuous data)

    HAGOS pain sub-item measures degree of hip and/or groin pain through ten individual questions on a score from 0 to 100, higher score indicates lower pain.

    From baseline to 6-month follow-up. Outcome measured at baseline, 3- and 6-month follow-up. In addition at 9- and 12-month follow-up (health economic study) and after 2, 5 and 10 years (describing if hip osteoarthritis progresses over time)

Secondary Outcomes (13)

  • Change in self-reported symptoms measured with HAGOS (continuous data)

    From baseline to 6-month follow-up. Outcome measured at baseline, 3- and 6-month follow-up. In addition at 9- and 12-month follow-up and after 2, 5 and 10 years (describing if hip osteoarthritis progresses over time)

  • Change in self-reported physical function, daily living (ADL) measured with HAGOS (continuous data)

    From baseline to 6-month follow-up. Outcome measured at baseline, 3- and 6-month follow-up. In addition at 9- and 12-month follow-up and after 2, 5 and 10 years (describing if hip osteoarthritis progresses over time)

  • Change in self-reported physical function in sports and recreational activities (sport/recreation) measured with HAGOS (continuous data)

    From baseline to 6-month follow-up. Outcome measured at baseline, 3- and 6-month follow-up. In addition at 9- and 12-month follow-up and after 2, 5 and 10 years (describing if hip osteoarthritis progresses over time)

  • Change in self-reported participation in physical activities (participation) measured with HAGOS (continuous data)

    From baseline to 6-month follow-up. Outcome measured at baseline, 3- and 6-month follow-up. In addition at 9- and 12-month follow-up and after 2, 5 and 10 years (describing if hip osteoarthritis progresses over time)

  • Change in self-reported quality of life (QOL) measured with HAGOS (continuous data)

    From baseline to 6-month follow-up. Outcome measured at baseline, 3- and 6-month follow-up. In addition at 9- and 12-month follow-up and after 2, 5 and 10 years (describing if hip osteoarthritis progresses over time)

  • +8 more secondary outcomes

Other Outcomes (23)

  • Self-reported acceptable symptom state using the Patient Acceptable Symptom State (PASS) (dichotome data)

    Measured at 6- and 12-month follow-up

  • Change in self-reported hip and/or groin pain intensity measured with a 100 mm Visual Analogue Scale (VAS) for pain in rest (continuous data)

    From baseline to 6-month follow-up. Outcome measured at baseline, 6- and 12-month follow-up

  • Change in self-reported hip and/or groin pain intensity measured with a 100 mm Visual Analogue Scale (VAS) for pain during physical activity (continuous data)

    From baseline to 6-month follow-up. Outcome measured at baseline, 6- and 12-month follow-up

  • +20 more other outcomes

Study Arms (2)

Exercise and patient education

EXPERIMENTAL

6-months

Other: Exercise and patient education

Usual Care

ACTIVE COMPARATOR

6-months

Other: Usual Care

Interventions

Over a period of 6-months, patients will be offered eight one-to-one supervised training sessions. In these sessions, patients will be instructed in a home-based exercise programme and given patient education. The programme includes four exercises covering strength and stability training. The exercises will be performed in sets of three with a minimum of 5 repetitions, and patients will be instructed to perform a minimum of three training sessions each week. Each of the exercises can be progressed through three levels of difficulty, allowing for individualised treatment with regard to exercise quality and perceived exertion according to the Borg CR10 scale. Exercises will be performed on a perceived exertion level from somewhat hard (level 5) to very hard (level 7). Patient education includes pain management, a focus on exercise adherence and progression, and advice on physical activity.

Exercise and patient education

Patients will follow usual care, including an individual consultation on self-management of hip symptoms and general advice on exercise and physical activity.

Usual Care

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Radiographically verified hip dysplasia by a Wiberg's centre edge (CE) angle of 10-25 degrees and an acetabular Index (AI) angle \>10 degrees
  • Hip and/or groin pain as primary pain for at least three months
  • Candidate for periacetabular osteotomy (PAO) but unwilling to undergo PAO, or on a waiting list for surgery (PAO) for 12 months or longer
  • Not candidate for PAO (negative impingement test, BMI \>25, hip osteoarthritis, age \>45 years or reduced hip range of motion)

You may not qualify if:

  • Self-reported pain score \>80 points measured with Copenhagen Hip and Groin outcome score
  • Any major planned surgery (i.e. arthroplastic surgery or discectomy surgery)
  • BMI \>35
  • Acetabular retroversion defined by crossover sign and posterior wall sign
  • Calvé Legg Perthes or epiphysiolysis
  • Previous pelvic/hip surgery in index limb
  • Previous pelvic/hip surgery within the last 2 years in contralateral limb
  • Previous surgery due to herniated disc or spondylodesis
  • Previous arthroplastic surgery in the hip, knee or ankle
  • Physical (pregnancy/trauma), neurological, medical or rheumatic conditions severely affecting the hip function
  • Inadequacy in written and spoken Danish, mental illness or other conditions affecting the ability to follow mandatory procedures for participation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Aarhus University Hospital

Aarhus N, 8200, Denmark

RECRUITING

Silkeborg Regional Hospital.

Silkeborg, 8600, Denmark

RECRUITING

Related Publications (3)

  • Jacobsen JS, Evans R, Morgan K, Thorborg K, Oestergaard LG, Sorensen D. An exercise and patient education intervention to reduce pain and physical limitations in adults with acetabular dysplasia: study protocol for a process evaluation integrated within a randomised controlled trial (the MovetheHip trial). Trials. 2024 Jun 24;25(1):411. doi: 10.1186/s13063-024-08262-y.

    PMID: 38915128BACKGROUND
  • Jacobsen JS, Thorborg K, Nielsen RO, Jakobsen SS, Foldager C, Sorensen D, Oestergaard LG, van Tulder MW, Mechlenburg I. Comparing exercise and patient education with usual care in the treatment of hip dysplasia: a protocol for a randomised controlled trial with 6-month follow-up (MovetheHip trial). BMJ Open. 2022 Sep 20;12(9):e064242. doi: 10.1136/bmjopen-2022-064242.

    PMID: 36127096BACKGROUND
  • Jacobsen JS, Thorborg K, Sorensen D, Jakobsen SS, Nielsen RO, Oestergaard LG, Soballe K, Mechlenburg I. Feasibility and acceptability of a six-month exercise and patient education intervention for patients with hip dysplasia: A mixed methods study. Musculoskelet Sci Pract. 2022 Oct;61:102615. doi: 10.1016/j.msksp.2022.102615. Epub 2022 Jun 24.

    PMID: 35820302BACKGROUND

MeSH Terms

Conditions

Hip DislocationHip Dislocation, CongenitalMotor Activity

Interventions

ExercisePatient Education as Topic

Condition Hierarchy (Ancestors)

Joint DislocationsJoint DiseasesMusculoskeletal DiseasesWounds and InjuriesHip InjuriesDevelopmental Dysplasia of the HipMusculoskeletal AbnormalitiesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesBehavior

Intervention Hierarchy (Ancestors)

Motor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological PhenomenaHealth EducationPreventive Health ServicesHealth ServicesHealth Care Facilities Workforce and Services

Study Officials

  • Julie S Jacobsen, PhD

    VIA University College

    PRINCIPAL INVESTIGATOR
  • Inger Mechlenburg, DMSc

    Aarhus University Hospital

    STUDY DIRECTOR
  • Kristian Thorborg, PhD

    Copenhagen University Hospital, Hvidovre

    STUDY CHAIR
  • Rasmus Ø Nielsen, PhD

    University of Aarhus

    STUDY CHAIR
  • Stig S Jakobsen, PhD

    Aarhus University Hospital

    STUDY CHAIR
  • Lisa G Oestergaard, PhD

    Defactum, Central Denmark Region

    STUDY CHAIR
  • Kjeld Søballe, PhD

    Aarhus University Hospital

    STUDY CHAIR

Central Study Contacts

Julie S Jacobsen, PhD

CONTACT

Inger Mechlenburg, DMSc

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 9, 2021

First Posted

March 12, 2021

Study Start

April 16, 2021

Primary Completion (Estimated)

July 1, 2027

Study Completion (Estimated)

December 1, 2027

Last Updated

December 5, 2025

Record last verified: 2025-11

Data Sharing

IPD Sharing
Will share

What data will be shared: All quantitative individual participant data collected during the trial, after deidentification. With whom will data be shared: Researchers who provide a methodologically sound proposal. For what types of analyses: To achieve aims in the approved proposal. The abovementioned is based on Data Sharing Statements for Clinical Trials: A Requirement of the ICMJE located at: http://www.icmje.org/news-and-editorials/data\_sharing\_june\_2017.pdf.

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
Immediately following publication and ending 5 years following primary article publication.
Access Criteria
Proposals should be directed to jsaj@via.dk. To gain access, data requestors will need to sign a data access agreement.

Locations